TY - JOUR
T1 - Managing hematological cancer patients during the COVID-19 pandemic
T2 - an ESMO-EHA Interdisciplinary Expert Consensus
AU - Buske, C.
AU - Dreyling, M.
AU - Alvarez-Larrán, A.
AU - Apperley, J.
AU - Arcaini, L.
AU - Besson, C.
AU - Bullinger, L.
AU - Corradini, P.
AU - Giovanni Della Porta, M.
AU - Dimopoulos, M.
AU - D'Sa, S.
AU - Eich, H. T.
AU - Foà, R.
AU - Ghia, P.
AU - da Silva, M. G.
AU - Gribben, J.
AU - Hajek, R.
AU - Harrison, C.
AU - Heuser, M.
AU - Kiesewetter, B.
AU - Kiladjian, J. J.
AU - Kröger, N.
AU - Moreau, P.
AU - Passweg, J. R.
AU - Peyvandi, F.
AU - Rea, D.
AU - Ribera, J. M.
AU - Robak, T.
AU - San-Miguel, J. F.
AU - Santini, V.
AU - Sanz, G.
AU - Sonneveld, P.
AU - von Lilienfeld-Toal, M.
AU - Wendtner, C.
AU - Pentheroudakis, G.
AU - Passamonti, F.
N1 - Funding Information: GP reports grants from Amgen, grants, personal fees and non-financial support from Merck, grants and non-financial support from AstraZeneca, grants and personal fees from Roche, grants and personal fees from BMS, grants from Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, outside the submitted work.
Publisher Copyright: © 2022 The Authors
PY - 2022/4
Y1 - 2022/4
N2 - Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.
AB - Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.
UR - http://www.scopus.com/inward/record.url?scp=85125770342&partnerID=8YFLogxK
U2 - 10.1016/j.esmoop.2022.100403
DO - 10.1016/j.esmoop.2022.100403
M3 - Article
C2 - 35272130
AN - SCOPUS:85125770342
SN - 2059-7029
VL - 7
JO - ESMO Open
JF - ESMO Open
IS - 2
M1 - 100403
ER -
